Tivic Health receives IRB approval from Feinstein Institutes for ncVNS optimization study

Valion Bio, Inc.

Received IRB approval from Feinstein Institutes for clinical optimization study of ncVNS; enrollment to commence.
Study will optimize stimulation parameters and electrode positioning using physiological measurements.
Data will guide selection of clinical populations and design of future disease-specific trials.
Collaboration with Fletcher Spaght to identify high-unmet-need clinical applications for ncVNS.
Global VNS market valued at $8.59B (2021), projected $21.3B by 2030, CAGR 10.6%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.